Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY25 results · Oct–Dec 2024
Suven Life Sciences reported revenue from operations of ₹1.61 crore (down 34.3% from Q3 FY24) and net loss of ₹39.12 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.61 | 2.45 | −34.3% | 2.57 | −37.4% |
| Other income | 1.63 | 6.07 | −73.1% | 4.04 | −59.6% |
| Total income | 3.24 | 8.52 | −62.0% | 6.61 | −51.0% |
| Profit before tax | (39.12) | (41.76) | Loss narrowed | (49.64) | Loss narrowed |
| Net profit for the period | (39.12) | (41.76) | Loss narrowed | (49.64) | Loss narrowed |
| EPS, basic (₹) | (1.79) | (1.92) | Loss narrowed | (2.27) | Loss narrowed |
| Net margin (%) | -2429.8 | -1704.1 | -1929.5 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.61 | 2.45 | −34.3% | 2.57 | −37.4% |
| Other income | 1.57 | 6.07 | −74.1% | 4.03 | −61.1% |
| Total income | 3.18 | 8.52 | −62.7% | 6.61 | −51.9% |
| Profit before tax | (13.27) | (4.77) | Loss widened | (11.07) | Loss widened |
| Net profit for the period | (13.27) | (4.77) | Loss widened | (11.07) | Loss widened |
| EPS, basic (₹) | (0.61) | (0.22) | Loss widened | (0.51) | Loss widened |
| Net margin (%) | -824.4 | -194.6 | -430.3 |
Consolidated
- Filed with BSE
- 24 Jan 2025, 19:06 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2025, 19:06 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE